Global RIA (Radio-Immuno Assays) market is about 500 M$ in 2024 and is expected grove at a CAGR of 4.0% during 2025 to 2034. The leading market will be Asia-Pacific and North America.

This trend reflects the persistent demand for highly sensitive and accurate tests, particularly for hormones and other low-concentration biomarkers. However, this growth is constantly under threat from a major challenge: the use of radioactive materials, which pose safety, regulatory, and environmental issues.

Our target is the entire market to replace RIA with hsELISA tests. Our basic difference will be 100-fold more sensitive tests without radioactivity.

Existing Solutions and Their Limitations 

 

Currently, the most widely used diagnostic methods are RIA (Radioimmunoassay) and conventional ELISA. RIA has long been considered the gold standard due to its exceptional sensitivity; however, the use of radioactive materials brings significant environmental risks, high disposal costs, and increasing regulatory restrictions, leading to a gradual decline in its use. Conventional ELISA tests, on the other hand, are safe and easy to apply but fail to reach RIA-level sensitivity when measuring low-concentration hormones or biomolecules. As a result, laboratories are seeking a new solution that combines the precision of RIA with the safety of ELISA. IDA-BV’s high-sensitivity ELISA (hsELISA) technology bridges this gap through an oligonucleotide-based signal amplification system, offering both RIA-like sensitivity and ELISA-grade safety within a single, environmentally friendly platform.

IDA-BV’s Innovation 

 

IDA-BV is developing a high-sensitivity ELISA (hsELISA) technology to fill a critical gap in current diagnostic testing methods. This innovative approach aims to increase the sensitivity of conventional ELISA tests by up to 100-fold, providing a safe and environmentally friendly alternative to radioactive assays. Our technology enhances signal detection by linking secondary antibodies with oligonucleotides, enabling the accurate and reliable measurement of very low concentrations of hormones and biomolecules. 

The system developed by IDA-BV offers significant advantages in terms of sensitivity, safety, and efficiency: 

Sensitivity: Provides RIA-comparable performance, allowing precise detection of low-concentration analytes. 

Safety: Eliminates the need for radioactive materials, improving laboratory safety and reducing environmental hazards. 

Efficiency: Easily integrates into existing laboratory workflows, enabling a smooth transition for laboratories currently using RIA tests.

With hsELISA, IDA-BV is redefining diagnostic precision — combining scientific innovation with sustainable progress to shape the future of laboratory testing.